Pharnext (FR:ALPHA) has released an update.
Pharnext SCA, a biopharmaceutical company focused on neurodegenerative diseases, has initiated liquidation proceedings after failing to secure funding post-conciliation. The Paris Commercial Court has appointed a liquidator and trading of Pharnext’s shares has been suspended. Shareholders are unlikely to receive any payment from asset sales due to the company’s liabilities and are warned of potential capital loss and share dilution.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
